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The composition and metabolic activity of the microbiome affect many aspects of 
health, and there is current interest in dietary constituents that may affect this system. The 
purpose of this study was to evaluate the effects of a mix of probiotics, a mix of 
prebiotics and a bioactive protein fraction on the microbiome, when fed to mice 
individually and in combination. Mice were fed the total western diet (TWD) 
supplemented with prebiotics, probiotics, and Tri-Factor (bioactive proteins) individually 
and in combination for four weeks. Subsequently, effects on the composition of gut 
microbiome, gut short chain fatty acids (SCFAs) concentration, gut inflammation and 
integrity of the mucosal barrier were analyzed. Ruminococcus gnavus was increased in 
mice gut microbiome after feeding prebiotics. Bifidobacterium longum was increased 
after feeding probiotics. Probiotic was associated with higher level of Clostridium 
neonatale. The treatments affected beta-diversity with exception of Tri-Factor, but not 
alpha diversity of microbiome. All treatments were associated with lower plasma zonulin, 
compared to the control group, indicating an effect on gut permeability. There were no 
treatment effects on cecal or fecal SCFAs, and the treatments did not affect gut 
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inflammation as measured by fecal calprotectin. 
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I. INTRODUCTION  
Prebiotics and probiotics are two common dietary supplements that have been 
shown to affect gut health in both rodent and human studies. Prebiotics are substrates that 
are utilized by select gut microorganisms, and which confer a health benefit (Gibson et 
al., 2017; Gibson, Probert, Van Loo, Rastall, & Roberfroid, 2004). Probiotics are bacteria 
that improve gut health, and which come predominantly from the Lactobacillus and 
Bifidobacterium genera (Colin Hill et al., 2014; C. Hill et al., 2014; Mack, 2005). Most 
prebiotics are oligosaccharides, which pass undigested through the small intestine to the 
colon and are fermented by intestinal bacteria and stimulate the growth of specific 
microbial taxa (Blaut, 2002; Rastall, 2010; Roberfroid, 2007). Probiotics are added as 
culture of fermented foods like yogurt and kefir or naturally present as starter on 
vegetable for kimchi and sauerkraut. They are also taken as supplements for human.  
There have been many model rodent and human clinical studies that have 
investigated the health benefits of prebiotics, probiotics and/or synbiotics (prebiotics and 
probiotics administered together). Such health benefits include promotion of gut 
fermentation, modulation of the microbiome composition, reduction of gut inflammation, 
decreased susceptibility to food allergy and prevention of cancer (I. Cho & Blaser, 2012; 
Swennen, Courtin, & Delcour, 2006). Suggested benefits of probiotics include 
improvement of the gut barrier function, increased competitive adherence to the mucosa 
and epithelium, gut microbiota modification, and regulation of the gut associated 
lymphoid immune system (Saez-Lara, Robles-Sanchez, Ruiz-Ojeda, Plaza-Diaz, & Gil, 
2016).  
In mice, many studies have reported large increases in cecal and fecal SCFAs 
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with prebiotic inclusion in the diet, which is likely due to the quantity. For example, 
mouse diets are often supplemented with 5-10% prebiotics (B. S. Hamilton et al., 2017; 
Murakami et al., 2015a; Nihei et al., 2018; Weitkunat et al., 2015a). Hamilton et al fed 
10% inulin or bovine milk oligosaccharides to mice on a high fat diet (4500 kcal/kg) 
which increased cecal butyrate and propionate (B. S. Hamilton et al., 2017). Weitkunat 
supplemented a high-fat diet in mice with 10% inulin, and acetate, propionate and 
butyrate were all increased in the cecum, as were total SCFAs (Nihei et al., 2018). Nihei 
et al include 5.5% cyclodextrin to a high-fat diet (~5250 kcal/kg) which was associated 
with an increase in all cecal SCFAs except n-valeric acid. Last, Murakami added 10% 
epilactose to both low and high fat diets which increase all cecal SCFAs except lactic 
acid (Murakami et al., 2015b). In the studies above, prebiotics were associated with 
impressive health benefits. For example, supplementation prevented adiposity 
development (B. S. Hamilton et al., 2017; Nihei et al., 2018), gut permeability (M. K. 
Hamilton et al., 2017), improved lipid metabolism (Nihei et al., 2018; Weitkunat et al., 
2015b), and increased energy expenditure (Murakami et al., 2015b; Nihei et al., 2018). 
In human trials, prebiotics are typically supplemented between 5 and 20 g/d 
(Childs et al., 2014; Finegold et al., 2014; Holscher et al., 2015; Lecerf et al., 2012; 
Rajkumar et al., 2015; Vandeputte et al., 2017; Wilms et al., 2016). Fecal SCFAs have 
been measured in some studies, and to date a clear effect has not been established. No 
change in fecal SCFAs was determined after 1.4 or 2.8 g/d XOS for 8 weeks (Finegold et 
al., 2014), or 5 and 7.5 g/d inulin for 21d (Holscher et al., 2015). Conversely, 
consumption of 5g/d XOS for 4 weeks increased fecal butyrate and decreased acetate, 
while a mix of 3g/d inulin and 1g/d XOS resulted in an increase in propionate and total 
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SCFAs (Lecerf et al., 2012). Childs et al provided subjects with 8g/d XOS and 109 CFU 
Bifidobacterium animalis subspecies lactis Bi-07, singly and in combination for 21d 
(Childs et al., 2014). Individually, both treatments reduced fecal acetate and butyrate, but 
the combination did not. In addition, the combination increased fecal iso-valeric acid. At 
higher intakes, prebiotics supplementation has been shown to increase fecal SCFAs, but 
is also associated with an increase in gastrointestinal stress. Clarke et al fed subjects 
either 3 × 5 g/d of a mixture of inulin and FOS or maltodextrin for 28d (Clarke et al., 
2016). The prebiotic supplementation significantly increased total fecal SCFAs, but was 
associated with significant increases in self-reported GI symptoms and headaches. More 
concerning, however, is the fact that the 15g/d prebiotic supplementation increased 
circulating inflammatory cytokines, the proportion of immune cells that expressed TLR2 
and TLR4, and the response to TLR2 agonists in an ex vivo assay. The authors suggested 
that increases in these markers, while moderate, were consistent with increased immune 
cell contact with microbial stimuli. 
Rodent studies suggest that substantial intakes of prebiotics may improve 
metabolic health, yet it is unclear if such levels can be achieved in human diets. To date, 
there has been little discussion in the literature on translating intakes of prebiotics 
between rodents and humans. A 25 g mouse consuming 2.5 g of food a day with 10% 
prebiotics will ingest 0.25 g, or 10g/kg. For a 70 kg, that translates to 700g of prebiotics 
per day. However, if nutrient density is used and the prebiotics are normalized to kcal, 
2.5g of a high fat diet (5000 kcal/g) with 10% prebiotics would deliver 20 mg/kcal. For a 
2500 kcal diet, an equivalent intake would be 50g/d, which is significantly higher than 
the Institute of Medicine’s recommendation for total dietary fiber, which is 14g/1000 kcal 
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(Institute_of_Medicine, 2005).  
The effects on gut microbiome were observed when administered only probiotics 
or combined with prebiotics. The changes in gut microbiome can contribute to an 
increased susceptibility to diseases both within and outside the gut (Cénit, Matzaraki, 
Tigchelaar, & Zhernakova, 2014). There have been a number of studies that have shown 
modification of gut microbiome when mice are supplemented with large doses of 
prebiotics, probiotics, individually or in combination (Carasi et al., 2015; W. Cheng et al., 
2017; W Cheng et al., 2018; Cortez-Pinto et al., 2016; Delbes et al., 2018; Foure et al., 
2018; Frece et al., 2009; Mariman, Tielen, Koning, & Nagelkerken, 2015; Nihei et al., 
2018; Singh et al., 2017; Wang et al., 2012). Changes are typically an increase in 
abundance of fecal Bifidobacteria, Lactobacilli and Alloprevotella (W. Cheng et al., 
2017; W Cheng et al., 2018; Delbes et al., 2018; Frece et al., 2009; M. K. Hamilton et al., 
2017; Mischke et al., 2018; Nihei et al., 2018; Singh et al., 2017). The Firmicutes / 
Bacteroidetes ratio has also been affected by treatments (Foure et al., 2018). An increased 
ratio of Firmicutes to Bacteroidetes was observed in obese versus lean subjects (Cénit et 
al., 2014; Turnbaugh et al., 2008). 
In general, the effectiveness of probiotics and prebiotics have been more 
substantial in rodent studies. Several factors may explain the inconsistence in results 
between mice and humans, including 1) the specific prebiotics and probiotics 
administered, 2) the method of delivery, 3) the duration of treatment, 4) the dosage used, 
and 5) fundamental differences between the two species.  
In rodents, prebiotic supplementation of diets is common at levels between 5.5% 
and 15% on a mass basis (W. Cheng et al., 2017; Delbes et al., 2018; M. K. Hamilton et 
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al., 2017; Nihei et al., 2018), which is high, considering total dietary fiber in the purified 
rodent diet, the AIN-93G, is only 5% by mass. In human studies, prebiotics have been 
given at levels between 5 to 20 g/day (Childs et al., 2014; Clarke et al., 2016; Finegold et 
al., 2014; Holscher et al., 2015; Lecerf et al., 2012; Rajkumar et al., 2015; Vandeputte et 
al., 2017; Wilms et al., 2016). A possible explanation for differences in results between 
rodent and human studies may be the amount given, yet there has not been much 
discussion in the literature of how to translate prebiotic intakes between species. If 
dosage levels are compared on a gram of prebiotic consumed per kilogram of body 
weight in mice and humans, the levels are approximately 60 times higher in rodent 
studies. Yet, body weight normalization does not take into account the increased 
metabolic rate of rodents. Allometric scaling is a method of interspecies comparison of 
basal nutrient requirements (Rucker, 2007), and may be more appropriate for translating 
intakes between species. One method of allometric scaling is nutrient density, wherein 
nutrients are expressed relative to calories. If the nutrient density of prebiotic 
supplementation is compared (mg prebiotic/kcal diet), then rodent studies typically 
supply 3-4 fold more that the human studies.  
In rodent studies, probiotics have been given in a range of 108 and 109 CFU/day 
for mice (Bai et al., 2016; Carasi et al., 2015; Mariman et al., 2015; Wang et al., 2012), 
and around 109 CFU/day for humans (Childs et al., 2014; Gargari et al., 2016; Lee et al., 
2017; Rajkumar et al., 2015; Rungsri et al., 2017; Seo et al., 2017; Toscano, De Grandi, 
Stronati, De Vecchi, & Drago, 2017; van Zanten et al., 2014). If probiotic intakes 
between rodents and humans are compared on a mass basis (i.e. 109 CFU for 75kg human 
vs. 108 CFU for 25g mouse), rodents are typically given ~150X more. When CFUs are 
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normalized to calorie intake (i.e. i.e. 109 CFU for 2500 kcal/d human vs. 108 CFU for 11 
kcal/d mouse), rodents are given ~10X more. In rodent studies, probiotics may be mixed 
in the food pellets (Delbes et al., 2018; Nihei et al., 2018) or administered via oral gavage 
(Carasi et al., 2015; Foure et al., 2018; Mariman et al., 2015; Singh et al., 2017; Wang et 
al., 2012). Additionally, probiotics have be added to the drinking water of the rodents 
(Bai et al., 2016; Umu et al., 2016). The advantage for oral gavage is the precise control 
of dosage, when compared to inclusion in the food or water. 
Tri-Factor® is a proprietary blend of low molecular weight bioactive proteins 
isolated from bovine colostrum and egg yolks (www.4life.com). Tri-Factor contains two 
ultra filtrates of colostrum, one with a molecular weight cut off of 10 kDa, and a second 
at 3 kDa. Low molecular weight colostrum proteins and peptides are rich in proline, and 
low in glycine, alanine, arginine and histidine, and do not contain tryptophan, methionine 
or cysteine (Szaniszlo et al., 2009). 
The overall objective of this study was to evaluate the effect of a human gut 
health supplement in a mouse model when provided at a physiologically relevant dose. 
As a control, mice were fed the TWD, a purified rodent diet that matches the average US 
intake of macro- and micronutrients (Hintze, Benninghoff, Cho, & Ward, 2018). The 
TWD was supplemented with either prebiotics, probiotics, or Tri-Factor, individually and 
in combination. The endpoints of interest were the effect on the composition of the gut 
microbiome, cecal and fecal short chain fatty acids (SCFAs), gut inflammation, and 
plasma zonulin.  
The overall hypothesis is that the treatments will increase the diversity of the 
microbiome and be associated with more SCFAs, less gut inflammation and an improved 
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mucosal barrier. Specifically, we predict the prebiotics treatment will increase the fecal 
microbiome diversity, the cecal SFCAs content and decrease fecal calprotectin. We 
anticipate the probiotics treatment will increase the fecal levels of the probiotics 
administered and reduce fecal calprotectin. The TF treatment will affect the microbiome 
composition, and the levels of gut inflammation. Last, the combined treatment is predicted 
to increase both the fecal microbiome diversity and SCFAs due to the presence of the 
probiotics and prebiotics, while it will reduce fecal calprotectin.  
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II. METHOD AND MATERIALS  
Diet formulation   
The treatment dosages were calculated using a nutrient density approach to 
convert the dosage of the human supplement (Pre/o Biotics, 4Life, Sandy, UT) to 
metabolically equivalent doses in mice (Table 1) The supplement, Pre/o Biotics contains 
2.5g of prebiotics with equal parts fructooligosaccharides (FOS), galactooligosaccharides 
(GOS) and xylooligosaccharides (XOS). In addition, Pre/o Biotics contains 0.5 × 109 
CFU of Bifidobacterium infantis (M-63), Bifidobacterium longum (BB536) and 
Bifidobacterium lactis (Bl-04), and 0.25 × 109 CFU Lactobacillus rhamnosus (Lr-32) and 
Lactobacillus acidophilus (NCFM). Last, Pre/o Biotics contains 100 mg of Tri-Factor, a 
proprietary concentrate of egg yolk and bovine colostrum proteins and peptides (4life, 
Sandy, UT).  
Table 1. Translation of human to mouse intakes using nutrient density 




2.5 g/d 2 × 109 CFU/d 100 mg/d 
Energy intake (kcal/d) 2500 2500 2500 




Translated dose 11 mg/d 
8.8 × 106 
CFU/kcal 
0.44 mg/d 
Energy intake (kcal/d) 11 11 11 
Nutrient density 1 mg/kcal 8 × 105 CFU/kcal 40 µg/kcal 
Actual dose§ 16.5 mg/d 1.3 × 107 CFU/d 0.66 mg/kcal 
§The prebiotic and Tri-Factor were increased by 1.5-fold and the probiotics by 3-fold to 




To convert the dosages using nutrient density, an average caloric intake of 2,500 
kcal/day was used for humans. For mice, 11 kcal was determined according to previous 
studies. The quantities of prebiotics, probiotics and Tri-Factor in Pre/o Biotics were 
normalized to an average human caloric intake (i.e. 2.5g prebiotics/2500 kcal = 1 
mg/kcal). This value was then used to determine the mass added to the TWD formulation, 
which has a 4400 kcal per kilogram. For the prebiotics, there should be 4.4 g of prebiotics 
per kg of diet (i.e. 1 mg/kcal * 4400 kcal), and similar calculations were made for the 
probiotics and Tri-Factor. To increase the likelihood of measuring treatment effects, the 
dose of prebiotics and Tri-Factor was increased 1.5-fold, and the probiotic treatment 3-
fold (Table 1).   
The control diet was the TWD, and for the treatment groups, a portion of 
maltodextrin was removed to account for the prebiotic, probiotic and Tri-Factor addition. 
The decision to replace maltodextrin was made as it has most often been used as a control 
in human prebiotic studies (Beserra et al., 2015; Fernandes, do Rosario, Mocellin, Kuntz, 
& Trindade, 2017). Diet assignments were as follows: 1) TWD: Total Western Diet as 
control: 2) PRE: prebiotics, 3) PRO: probiotics, 4) TF: Tri-Factor, 5) COM: prebiotics, 
probiotics and Tri-Factor. The composition of the diets is shown in Table 2. All diets 








Table 2. Composition of experimental diets 
Diet composition TWD PRE PRO TF COM 
Treatment (g/kg) 
Prebiotic § - 6.75 - - 6.75 
Probiotic - - 0.15 - 0.15 
Tri-Factor - - - 0.26 0.26 
Carbohydrate (g/kg) 
Cellulose 30 30 30 30 30 
Corn starch 230.0 230.0 230.0 230.0 230.0 
Maltodextrin ‡ 70.0 63.2 69.7 69.6 62.7 
Sucrose 261.3 261.3 261.3 261.3 261.3 
Protein (g/kg)      
Casein 190 190 190 190 190 
L-cysteine 2.85 2.85 2.85 2.85 2.85 
Fat (g/kg) 
Anhydrous milk fat 36.3 36.3 36.3 36.3 36.3 
Beef tallow 24.8 24.8 24.8 24.8 24.8 
Cholesterol 0.4 0.4 0.4 0.4 0.4 
Corn Oil 16.5 16.5 16.5 16.5 16.5 
Lard 28 28 28 28 28 
Olive oil 28 28 28 28 28 
Soybean oil 31.4 31.4 31.4 31.4 31.4 
Vitamin, mineral, antioxidant (g/kg) 
Mineral mix 35 35 35 35 35 
Vitamin mix 10 10 10 10 10 
Sodium chloride 4 4 4 4 4 
Choline bitartrate 1.4 1.4 1.4 1.4 1.4 
TBHQ 0.028 0.028 0.028 0.028 0.028 
% Kcal 
Protein 15.5 15.5 15.5 15.5 15.5 
Carbohydrate 50.0 49.7 50.0 50.0 49.7 
Fat 34.5 34.7 34.5 34.5 34.7 
Calorie (Kcal/g) 4.4 4.3 4.4 4.4 4.3 
§The prebiotics contained equal parts FOS, GOS and XOS. 





C57Bl/6J male mice were purchased from Jackson Laboratories (Bar Harbor, 
ME). Mice were randomly assigned by weight to each treatment for 4 weeks. Mice were 
individually housed in HEPA-filtered micro isolator cages. A 12-hour light/dark cycle 
was used, and the room temperature was kept between 18-23°C with humidity between 
20-50%. All animal care and husbandry procedures were performed under the Animal 
Welfare Act and the Public Health Service Policy on Humane Care and Use of 
Laboratory Animals, as well as USU Institutional Animal Care and Use Committee 
(protocol #2640). The experimental design is shown in Figure 1.  
 
Figure 1. Study design for dietary supplement 
Food intake and body weight were measured twice weekly. At the end of 
intervention, mice were killed by CO2 asphyxiation. Blood was removed by cardiac 
puncture and plasma was separated from whole blood via centrifugation. Plasma was 
aliquoted into microcentrifuge tubes and snap frozen in liquid nitrogen. Both fecal and 
cecal samples were collected at the end of intervention and snap frozen in liquid nitrogen 




TWD: total western diet (n=9)
TF: Tri-Factor group (n=10)
PRE: prebiotics group(n=10) FOS, GOS, XOS
COM: combination group 
(n=10)
PRE+PRO+TF
PRO: probiotics group (n=10)




Diet probiotic enumeration 
Diet samples were sent to Covance Laboratory (Madison, WI) for Total Probiotic 
Enumeration using standard plate procedures (Schoeni, 2013).  
SCFAs analysis  
SCFAs were extracted from fecal and cecal samples at the end of intervention, 
and measured by gas chromatography with flame ionization detection (GC-FID) 
according to the method from Ward et al (Ward et al., 2016).  
Gut Microbiome  
Taxonomic measures of the fecal microbiome were performed using 16s rRNA 
sequencing. The fecal samples collected at the terminal necropsy were used for this 
analysis. Bacterial DNA from the fecal samples was extracted using the QIAGEN 
QIAamp DNA Stool Mini Kit (Hilden, Germany) according to the manufacturer’s 
instructions. This extraction process involves homogenization and lysis of the stool using 
a stool lysis buffer and bead beater, and removal of inhibitors. 
After DNA extraction, samples were analyzed by spectroscopy to determine the 
concentration of DNA for each sample and then diluted with TE buffer to a concentration 
of 1 ng/µL. Samples were amplified via PCR, using barcoded primers directed against the 
V3 region of the 16S rRNA (Milani et al., 2013). PCR amplification was performed using 
the following protocol: 5 minutes at 95°C; 35 cycles of 94°C for 30 seconds, 55°C for 30 
seconds and 72°C for 90 seconds; final annealing at 72°C for 10 minutes; hold at 4°C.   
Following PCR amplification, gel electrophoresis was performed to visualize 
amplicons. The PCR products were then purified using AMPure microbeads. Once all the 
samples were purified, DNA concentration was assessed using the Picogreen assay, 
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which measures fluorescence via spectrophotometry to determine DNA concentration. 
Samples were then diluted to 1 ng/µL with TE buffer and pooled together into a single 
tube. Sequencing was performed at the Utah State Center for Integrated Biotechnology 
core sequencing facility using the Ion PGM System and analyzed using Ion Reporter™ 
workflow.  
Sequences were processed with the latest version of MacQIIME (Caporaso et al., 
2010). Sequences were filtered for quality and assigned operational taxonomic units 
(OTUs) (Schloss et al., 2009) at a 97% sequence similarity as compared to a reference 
GreenGenes OTU database (gg_13_8_otus). Sequences were assigned using the open-
reference OTU picking methodology with UCLUST (DeSantis et al., 2006). Sequences at 
the highest levels of abundance were chosen as representative sequences, and these were 
checked for chimeras using uchime61 (Edgar, Haas, Clemente, Quince, & Knight, 2011). 
Alpha diversity, beta diversity, and taxonomic summaries were performed using the 
core_diversity_analyses.py script. For diversity analyses, sequence depth was rarified to 
the sample with the fewest sequences. 
Gut inflammation 
Fecal calprotectin was extracted by with the following extraction buffer: 0.1 M 
Tris, 0.15 M NaCl, 1.0 M urea, 10 mM CaCl2, 0.1 M citric acid monohydrate and 5 g/L 
BSA (pH 8.0). After extraction and centrifugation, the supernatant was used for the 
ELISA analysis with a commercial kit following manufacturer’s instructions (Hycult Inc, 
Wayne, PA).  
Plasma zonulin 
Plasma samples were analyzed using a commercial ELISA kit according to 
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manufacturer’s directions (MyBioSource, San Diego, CA).  
Statistics analysis 
Treatment effects and interactions were determined by one way-ANOVA with 
Dunnett’s test. Pairwise analysis was used in microbiome results to compare each 
treatment with TWD group. For all statistical tests, a p value <0.05 (two-tailed test) was 
considered as significant. Transformations were used to equalize variance prior to the 
statistical analyses in cases where variance assumptions were not met.  
Because microbiome taxonomy data typically are not normally distributed due to 
zero-inflation, the effects of diet on relative taxonomic abundance were determined 
separately as one-way, non-parametric analyses. For these analyses, OTUs were 
normalized to sequences per million for each sample and then merged by the highest-
level classification (to species, if available), family, and phylum taxonomy levels. Single 
factor comparisons (PRE, PRO, TF, and COM vs TWD) at the phylum, family, and 
genus level were then made and tested for significance using the Kruskal-Wallis test and 
results corrected for multiple testing effects by the false discovery rate (FDR) test. 
Statistical analysis of beta diversity data was performed using the non-parametric 
PERMANOVA measure, which partitions a distance matrix among sources of variation 
in order to describe the strength and significance that an experimental variable has in 





Diet probiotic content 
The probiotics were added to the PRO and COM diets as powders, and plate 
counts were conducted by a third party to enumerate the CFUs in each diet. These 
numbers were then used to determine the average probiotic intake for each diet (Table 3). 
In the TWD and TF diets, the probiotic plate counts were below the detection limit of the 
assay, which is not surprising, as probiotics were not added to the diets. The PRE diet did 
contain a measurable level of probiotics, which presumably were introduced in the 
prebiotic powders. The COM diet contained the highest level of probiotics, followed by 
the PRO diet.    
Table 3. Probiotic enumeration for diets, and estimated probiotic intake/d 
Treatment TWD PRE PRO TF COM 
CFU/g diet <1 × 104 2 × 104 9 × 104  <1 × 104  3.4 × 105  
CFU/d‡ <2.4 × 104 5.5 × 104 2.6 × 105 <2.7 × 104 9 × 106 
‡Probiotic intake was estimated using CFU/g content measured in diets and average 
mass of food consumed per group. 
Food intake, weight gain, metabolic efficiency and probiotic intake.  
Mice consumed significantly more calories on the PRO diet than the TWD (Table 
4), but there were no other differences in intake among the diets. There was no treatment 







Table 4. Food intake, weight gain, and metabolic efficiency 
Treatment  TWD PRE PRO TF COM 
Energy intake 
(Kcal/day) 
10.8±0.2a 12.1±0.2ab 12.9±0.5b 12.2±0.4ab 11.7±0.4ab 
Weight gain (g) 6.6±0.5 8.0±0.5 7.7±0.5 6.4±0.4 7.4±0.6 
Metabolic efficiency 
(g/kcal) 
0.61±0.04 0.66±0.04 0.60±0.04 0.53±0.03 0.63±0.05 
Values with different superscripts differed significantly (p<0.05).   
SCFAs 
There were very few differences in the SCFAs content of the cecal or fecal 
contents (Table 5). In the cecal contents, only caproic acid differed significantly between 
the treatments, with all treatments being higher than the control. In feces, there was a 
trend (p<0.1) for differences in iso-butyric and valeric acids.  
When the TWD and COM treatments are compared directly, there was more 
butyric and caproic acid in the cecal contents, and more acetic and butyric acid in the 












Table 5. SCFAs in cecal and fecal samples for treatments  
Cecal SCFAs 
(mol/g) 
TWD PRE PRO TF COM 
p-
value  
Acetic acid 27.8±2.1 26.3±2.5 26.4±1.7 28.9±2.1 28.3±1.3 0.84 
Propionic acid 3.87±0.28 3.88±0.29 4.58±0.30 4.11±0.28 4.61±0.33 0.22 
n-Butyric acid 3.02±0.30 3.30±0.43 3.38±0.23 3.62±0.35 4.00±0.35 0.33 
iso-Butyric acid 0.48±0.01 0.44±0.03 0.47±0.01 0.44±0.02 0.47±0.01 0.47 
iso-Valeric acid 0.53±0.01 0.49±0.02 0.51±0.02 0.51±0.03 0.52±0.03 0.79 
n-Valeric acid 0.51±0.02 0.48±0.04 0.49±0.04 0.52±0.05 0.52±0.03 0.86 
Caproic acid 0.05±0.01 0.06±0.01 0.06±0.01 0.06±0.01 0.06±0.01 0.05 
Fecal SCFAs 
(mol/g) 
TWD  PRE PRO TF COM 
p-
value  
Acetic acid 20.4±2.1 28.0±2.5 25.5±4.5 22.8±1.8 27.2±1.9 0.27 
Propionic acid 2.2±0.3 2.6±0.2 2.1±0.3 2.6±0.3 2.8±0.2 0.20 
n-Butyric acid 0.70±0.10 0.97±0.17 0.87±0.08 1.05±0.12 1.03±0.10 0.26 
iso-Butyric acid 0.26±0.03 0.37±0.04 0.25±0.03 0.35±0.05 0.32±0.02 0.06 
iso-Valeric acid 0.43±0.05 0.58±0.05 0.45±0.03 0.55±0.07 0.52±0.02 0.21 
n-Valeric acid 0.19±0.03 0.26±0.04 0.14±0.02 0.31±0.08 0.19±0.02 0.10 
Caproic acid 0.06±0.01 0.17±0.06 0.09±0.02 0.20±0.10 0.11±0.03 0.39 

































































Figure 2. SCFAs analysis, data represent as mean ± SE (mol/g). A, butyric acid in cecal 
samples, p=0.044. B, caproic acid in cecal samples, p=0.022. C, acetic acid in fecal 
samples, p=0.025. D, butyric acid in fecal samples, p=0.037. 
Microbiome  
Taxonomic Summaries 
After quality, chimera, and abundance filtering, sequences were assigned to OTUs 
using the pick_open_ref_otus command for an average of 46853 sequences per sample 
assigned to 1546 OTUs. Compared to diet, PRE, PRO and COM treatments changed the 
microbiome composition. Figure 3 showed the family level taxonomy. 
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Figure 3. Family level taxonomy, percentage of total OTUs 
Because the differences in taxonomic relative abundance did not follow a normal 
distribution, these analyses were performed using non-parametric, single factor 
comparisons. A complete summary of significant differences in relative abundance is 











Table 6. Significant effect of treatment on taxonomic abundance compared to TWD 
Taxonomic Abundance 
p-value, each group compared to TWD) 
Direction* 
PRE PRO TF COM 
Class Actinobacteria / 0.0059 / / PRO 
Order Bifidobacteriales / 0.0047 / 0.0226 PRO, COM 
Family Bifidobacteriaceae / 0.0078 / 0.0438 PRO, COM 
Genus 
Ruminococcus 0.0065 / / / PRE 
Bifidobacterium / 0.0081 / / PRO 
Species 
gnavus 0.0004 / / 0.0017 PRE, COM 
longum / 0.0019 / 0.0069 PRO, COM 
neonatale / 0.0321 / / PRO 
*Note: Direction denotes a greater relative abundance in the study group mentioned 
Ruminococcus gnavus was increased after feeding prebiotics. The increasing was 
observed both in PRE and COM. Bifidobacterium longum was increased in mice gut 
microbiome after feeding probiotics. The increasing of Bifidobacteriaceae was consistent 
in PRO and COM. Besides, PRO was associated with higher level of Clostridium 
neonatale. 
Microbiome diversity 
Alpha diversity refers to within-habitat diversity. It is the component of total 
diversity that can be attributed to the average number of species found within 
homogeneous sampling units (i.e. habitats) (Gering & Crist, 2002). Alpha diversity was 
determined using Chao1 index. The analyses showed that no significant difference 






A. PRE vs TWD                                              B. PRO vs TWD 
  
 
C. TF vs TWD                                              D. COM vs TWD 
  
Figure 4. Alpha-diversity of gut microbiome, expressed by OTUs. A, PRE vs TWD, 
p=0.243: B, PRO vs TWD, p=0.673: C, TF vs TWD, p=0.277: D, COM vs TWD, 
p=0.720 
Beta diversity is referred to between-habitat diversity. It is the component of total 
diversity that can be attributed to differences in species composition among the 
homogeneous units in the landscape (Gering & Crist, 2002). Figure 5 is a spatial 
representation of beta diversity with Principle Coordinate Analysis. The treatment 





A. PRE vs TWD                                              B. PRO vs TWD 
  
 
C. TF vs TWD                                              D. COM vs TWD 
  
Figure 5. Beta-diversity of gut microbiome, unweighted unifrac distance with non-
parametric PERMANOVA test. A, PRE vs TWD, p=0.021: B, PRO vs TWD, p=0.015: 
C, TF vs TWD, p=0.415: D, COM vs TWD, p=0.005 
Gut inflammation  
The effect of diets on fecal calprotectin is shown in Figure 6. Prior to being 
randomized to the treatments, fecal samples were collected from mice consuming a 
standard laboratory chow diet. According to the data, mice consuming chow had lower 
levels of fecal calprotectin than mice on any of the treatment diets. After 4-week 
intervention on TWD and other treatments, mice showed higher level of fecal 






























Figure 6. Fecal calprotectin.  Data represent mean ± SE (g/g)  
Gut permeability  
Zonulin is peptide measured in plasma, and which is associated with an impaired 
gut barrier. According to Figure 7, plasma zonulin was lower in mice fed the PRE, PRO, 



























Figure 7. Plasma zonulin. Data represent mean ± SE (ng/ml). Different letters represent 




Enumeration of probiotic bacteria from the PRO and COM diets was lower than 
expected, as a 3-fold increase over the human dose was added to the diets (Table 2). It is 
likely the low recovery is due to the process of diet manufacture, and the labile nature of 
the added probiotics. Nonetheless, mice consuming these diets received levels between 
105 and 106 CFUs per day, which have been associated with significant physiological 
effects in previous rodent studies (Poutahidis et al., 2014). It was not expected that there 
would be measurable probiotics in the PRE diet, as the only addition to this diet were the 
prebiotics. It seems, therefore, that the added powders may contain microbes measured in 
the probiotic plate count method (Schoeni, 2013). 
Mice consuming the PRO diet consumed significantly more calories per day than 
mice consuming the TWD (Table 4). Yet, the increased calorie consumption was not 
associated with a greater weight gain, nor metabolic efficiency due to 4-week 
intervention.   
There were few differences in either the cecal or fecal concentration of SCFAs 
due to inclusion of either the prebiotics, probiotics or both. While compared to previous 
rodent studies, there were much lower level of treatment which administered and lead to 
the insignificant results.  
Similarly, as actual dosage for mice was much lower than previous animal study, 
there was no significant difference in phylum level abundance or Firmicutes to 
Bacteroidetes ratio. Prebiotics and probiotics affected microbiome by increasing 
Bifidobacterium longum and Ruminococcus gnavus, respectively. COM showed the same 
effect of modification as PRE and PRO due to it combined both prebiotics and probiotics. 
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An increasing of Ruminococcus gnavus was found in fecal microbiome in in patients with 
Crohn's disease, an inflammatory bowel disease (IBD) (Scaldaferri et al., 2013). It is 
suggested that prebiotics might had potential to promote inflammation.  
Bifidobacterium longum was one of probiotics supplied in diet in this experiment. 
Although the dosage for total probiotics was much lower than out expectation, we 
detected an increasing of Bifidobacterium longum in PRO diet compared to TWD, which 
suggested the effect of supplements was pronounced. Besides, PRO was associated with 
higher level of Clostridium neonatale. It is a strain that digested milk with gas 
production. Acetic, lactic and butyric acids are detected as metabolic products (Bernard, 
Burdz, Wiebe, Alfa, & Bernier, 2018).  
Alpha-diversity and beta-diversity are often used to evaluate the variation of 
microbiome composition. The diversity analysis would give a better understanding of 
similarity, replacement and richness difference within site and among site (Legendre, 
2014). Gut microbiome diversity was negatively associated with weight gain, while it 
was positively correlated with fiber intake. Besides, inflammatory bowel diseases (IBD) 
patients show an overall decreased gut bacteria diversity with a reduction of the dominant 
Firmicutes and Bacteroidetes compared to healthy people(Manichanh et al., 2006; Sokol, 
Lay, Seksik, & Tannock, 2008). When mice supplied with prebiotics or probiotics, 
enriched microbiome diversity was reported in some studies (W. Cheng et al., 2017; M. 
K. Hamilton et al., 2017; Park et al., 2013; Umu et al., 2016). But there was controversy 
of non-affect microbiome diversity with a lower dosage or short intervention supplement 
(Bai et al., 2016). Human trial reported that microbiome diversity was not affected by 
prebiotics or probiotics (Finegold et al., 2014; Holscher et al., 2015; Toscano et al., 2017; 
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van Zanten et al., 2014; Vandeputte et al., 2017). We used the reality dosage for mice 
rather than megadose, which concluded that the treatment diets did not affect alpha-
diversity, but affected beta-diversity with exception of TF treatment.  
Calprotectin is a Ca2+ binding protein produced by neutrophils (Fallahi et al., 
2013) which is bacteriostatic and fungistatic, and which has a minimum inhibitory 
concentration similar to antibiotics (Bunn et al., 2001). Calprotectin is important for the 
clearance of infection, as has been shown by the comparison of wild-type and 
calprotectin-deficient animals (Urban et al., 2009). Calprotectin can be used to predict 
relapses and detect pouchitis in IBD patients, and is used for IBD in undiagnosed, 
symptomatic patients(Konikoff & Denson, 2006). Several mice studies showed that 
megadose of prebiotics and probiotics supplied with high fat diet improved the 
inflammation situation (Carasi et al., 2015; Garcia, Dogi, de Moreno de LeBlanc, Greco, 
& Cavaglieri, 2016; Murakami et al., 2015a; Park et al., 2013; Singh et al., 2017). 
However, a debate was demonstrated from a 2 weeks synbiotics research which showed 
no effect on gut inflammation and permeability (Wilms et al., 2016). In our case, non-
significant difference of calprotectin suggested that treatment did not affect the 
inflammation situation on healthy mice. 
All mice were in Chow diet before intervention. Regular chow is composed of 
agricultural byproducts. It is a high fiber diet containing complex carbohydrates, with fats 
from a variety of vegetable sources(Warden & Fisler, 2008). When the mice were 
assigned a relatively high carbohydrates and high fat diet, TWD and other modified 
TWD, all treatment showed higher fecal calprotectin compare to Chow diet (Figure 6) 
after intervention.  
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Zonulin is a 47 kDa protein, with structural similarity to zonula occludens toxin 
(ZOT), which is synthesized in the intestine and reversibly regulates the gut barrier 
(Fasano, 2000; Fasano et al., 2000). Zonulin has been identified as pre haptoglobin-2 
(HP2) which is one of two human alleles of the haptoglobin gene (Tripathi et al., 2009). 
Interestingly, HP2, and thus zonulin, is only found in humans (Levy et al., 2010). Yet, 
ELISA antibodies to zonulin appear to measure other members of the zonulin family, 
such as properdin (A. Fasano, personal communication). A synthetic peptide, AT1001, 
contains the receptor-binding motif and is a zonulin inhibitor. In IL-10 knockout mice, 
treatment with AT1001 reduces intestinal permeability, and reduces colitis (Arrieta, 
Madsen, Doyle, & Meddings, 2009). In mice fed high fat diets, plasma zonulin levels are 
positively correlated with hepatic lipid content (Kwon, Lee, Seo, & Kim, 2019), weight 
gain and adipose tissue weight (Y. J. Cho, Lee, Seo, Yokoyama, & Kim, 2018). In the 
current study, all treatments led a significant reduction in plasma zonulin, compared to 
the control. Yet, the effect was not additive in the COM treatment. Furthermore, the 
reduction in plasma zonulin was not associated with fecal calprotectin, nor weight gain. 
There is no additional effect of Tri-Factor on mice weight and metabolic, gut 
fermentation, gut microbiome and inflammation. Additive effect was observed on gut 
microbiome when administered prebiotics and probiotics combinedly.  
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V. CONCLUSION  
Overall, for 1-month intervention, probiotic supplementation increased 
Bifidobacterium longum and Clostridium neonatale, while the prebiotic supplementation 
increased Ruminococcus gnavus. Combined prebiotic and probiotic administration 
increased Ruminococcus gnavus and Bifidobacterium longum as additive effect. The 
treatments did not affect alpha diversity, but affected beta-diversity with exception of Tri-
Factor. All treatments were associated with less plasma zonulin, compared to the control 
group, indicating an effect on gut permeability. There were no treatment effects on cecal 
or fecal short chain fatty acid levels, and the treatments did not affect gut inflammation as 
measured by fecal calprotectin.  
Physiologically relevant doses of dietary supplements for mice modified gut 
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